Skip to main content
  • Letter to the Editor
  • Open access
  • Published:

Letter to the editor: Vitamin D levels in acute illness and clinical severity in COVID-19 patients


We would like to comment on the recently published article titled: “Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients” by Ricci et al. The authors grouped the patients into two groups according to the vitamin D levels measured at the time of admission into the hospital and reported that lower vitamin D levels are associated with elevated D-dimer and IL-6 levels, low CD4/CD8 ratio and compromised clinical findings with elevated LIPI and SOFA scores. However, review of recent literature shows this association to be debatable. The 25-hydroxyvitamin D levels in the initial phase of critical illness have been reported to drop rapidly and hence consideration of the time of measurement from symptom onset would have enhanced the clinical relevance of these findings. Inferred association between vitamin D levels and disease severity based on SOFA score in COVID-19 patients, needs to be further explored in the light of the recent literature which casts doubt on using SOFA score at admission to predict mortality in COVID-19.


We read with great interest the article entitled: “Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients” by Ricci et al. [1]. The authors enrolled 52 COVID-19 patients in the study and collected vitamin D levels in the acute phase of the disease and concluded that lower vitamin D levels are associated with elevated D-dimer and Interleukin-6 (IL-6) levels, low CD4/CD8 ratio and compromised clinical findings with elevated Lung Immune Prognosis Index (LIPI) and Sequential Organ Failure Assessment (SOFA) scores.

A recently published metanalysis conducted by Kazemi et al. [2] showed equivocal outcomes of vitamin D deficiency and mortality association and inconsistent results of the association between vitamin D deficiency and pulmonary infiltrates/inflammation in COVID-19. Vitamin D insufficiency is common in hospitalized patients with acute illness especially in critically ill patients [3,4,5]. Serum 25-hydroxyvitamin D levels measured during the time of acute illness may be an unreliable biomarker of vitamin D status [6]. Thus, the vitamin D levels, that were measured after the onset of acute inflammatory insult in this study by Ricci et al., might reflect the acute phase of the disease rather than true vitamin D levels. Future studies should consider measuring vitamin D levels before the acute insult. If the measurement is done during the acute phase of the illness, consideration should be given to the days from symptom onset at the time of measuring vitamin D levels. Since different patients might present to the hospital at different stages of the acute illness and studies have noted rapid changes in the 25-hydroxyvitamin D levels in the initial phase of critical illness [7].

In addition, a variety of factors might affect vitamin D binding proteins and 25-hydroxyvitamin D levels including race, age, gender, obesity, chronic liver and kidney disease, diabetes and primary hyperparathyroidism [6]. Growing number of observational studies report significant association between preexisting comorbidities and clinical outcomes in COVID-19 patients [8,9,10,11]. In the study by Ricci et al., majority of patients were elderly, but consideration to various preexisting comorbidities and heterogeneity of race is missing, which undermines the clinical relevance of the results of this study.

A number of recent studies suggest inflammatory cytokine especially higher IL-6 associated with COVID-19 severity and survival [12,13,14]. A review of the literature looking at the association between vitamin D deficiency and IL-6 levels offers mixed evidence. Study by Radujkovic et al.[15] noted elevated IL-6 levels among patients with vitamin D deficiency similar to what has been noted by Ricci et al., whereas several other studies report no such association[16,17,18,19]. Similar conflicting results have been noted for elevated D-dimer levels, with many studies reporting no statistical significance [16, 19, 20], thereby further research is needed to elucidate this association as noted by the authors. Additionally Ricci et al. noted increased lung lesions in patients with low vitamin D levels similar to the study by Abrishami et al. [21] wherein they noted higher vitamin D levels associated with decreased amount of lung involvement on imaging, whereas Pizzini et al. [20] noted no such association. Ricci et al. also report that the patients with more severe COVID-19 disease had lower Vitamin D plasma levels regardless of age, whereas there is no mention of any subgroup analysis based on age, or the value of interaction between vitamin D levels and age in their statistical model. Hence it might be prudent to exercise caution while interpreting this statement.

We had earlier conducted a study looking at vitamin D levels and clinical outcomes in COVID-19 patients [22], wherein vitamin D levels were classified as ≥ 20 ng/mL (patients with normal vitamin D levels) and < 20 ng/mL (patients with low vitamin D levels). We found no significant association of vitamin D levels with mortality, the need for mechanical ventilation, intensive care unit (ICU) admission, and thromboembolism in COVID-19. Optimal levels of 25-hydroxyvitamin D for bone and general health have not yet been established [23,24,25] and most experts agree that vitamin D deficiency should be defined as 25-hydroxyvitamin D of < 20 ng/ml [26], it would have been of interest if the authors Ricci et al. had conducted further analysis looking at the results with vitamin D levels < 20 ng/mL and ≥ 20 ng/mL. Our data consisted of COVID-19 positive patients who presented to the hospital and had documented vitamin D, 25-OH level within the past 12 months. In the cohort of our study [22], there were 117 males (43.3%) and 153 females (56.7%). The mean age of patients was 63.81 years (mean ± SD, 14.69). More than half of the patients (n = 139, 51.5%) were in the 65 and older age group, with Blacks being the predominant race (n = 216, 80%). We conducted further exploratory analysis on our data and reclassified vitamin D levels as < 10 ng/mL and ≥ 10 ng/mL (as done by Ricci et al.). Vitamin D level < 10 ng/mL was seen in 39 (14.4%) patients and ≥ 10 ng/mL was seen in 231 (85.6%) patients. After adjusting for age, sex, race, BMI and presence of comorbidities using binary logistic regression, no significant association was seen with mortality (OR = 0.85; 95% CI, 0.33–2.17; p = 0.73), need for ICU admission (OR = 0.95; 95% CI, 0.44–2.06; p = 0.9) or mechanical ventilation (OR = 0.55; 95% CI, 0.20–1.49; p = 0.24). Additionally, no significant difference was seen in laboratory values (within 24 h of admission using Chi square test)- lymphopenia (Absolute lymphocyte counts less than 1000 per microliter) (17 v/s 111 patients, p = 0.57), ferritin > 300 ng/mL (19 v/s 131 patients, p = 0.47) and D-dimer > 2 mg/L (15 v/s 76 patients, p = 0.29), between the two groups (patients with vitamin D levels as < 10 ng/mL, and patients with vitamin D levels ≥ 10 ng/mL). Some of the recent studies note that SOFA score at presentation is less accurate in predicting mortality or the need for mechanical ventilation in COVID-19 patients [27, 28]. In the study by Ricci et al. they note higher SOFA scores in patients with vitamin D levels < 10 ng/mL however no significant association with mortality was noted as acknowledged by the authors, we advise a word of caution since the authors report the association between worse outcomes and low vitamin D levels based on elevated SOFA scores.

Notwithstanding these limitations, Ricci et al. illustrate a relationship between low vitamin D levels and inflammatory markers and radiological findings seen in COVID-19 patients. Consideration to address these limitations in future studies would immensely enhance the clinical relevance of these findings. Ideally, vitamin D levels immediately preceding the acute illness should be used to study the association of vitamin D with disease severity. Large community-based studies and randomized clinical trials of vitamin D supplementation in deficiency patients can unravel the enigma of possible role of vitamin D in the disease progression and severity of symptoms in COVID-19 patients.

Availability of data and materials

The deidentified data that support the findings of this study can be available from the corresponding author upon reasonable request and appropriate permission from the institutional IRB.





Lung Immune Prognosis Index


Sequential Organ Failure Assessment


Intensive care unit


Odds ratio


Confidence interval


Standard deviation


  1. Ricci A, Pagliuca A, D’Ascanio M, Innammorato M, De Vitis C, Mancini R, Giovagnoli S, Facchiano F, Sposato B, Anibaldi P, et al. Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients. Respir Res. 2021;22:76.

    Article  CAS  Google Scholar 

  2. Kazemi A, Mohammadi V, Aghababaee SK, Golzarand M, Clark CCT, Babajafari S. Association of Vitamin D status with SARS-CoV-2 infection or COVID-19 severity: a systematic review and meta-analysis. Adv Nutr. 2021.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Leaf DE, Croy HE, Abrahams SJ, Raed A, Waikar SS. Cathelicidin antimicrobial protein, vitamin D, and risk of death in critically ill patients. Crit Care. 2015;19:80.

    Article  Google Scholar 

  4. Brook K, Camargo CA, Christopher KB, Quraishi SA. Admission vitamin D status is associated with discharge destination in critically ill surgical patients. Ann Intensive Care. 2015;5:23.

    Article  Google Scholar 

  5. Czarnik T, Czarnik A, Gawda R, Gawor M, Piwoda M, Marszalski M, Maj M, Chrzan O, Said R, Rusek-Skora M, et al. Vitamin D kinetics in the acute phase of critical illness: a prospective observational study. J Crit Care. 2018;43:294–9.

    Article  CAS  Google Scholar 

  6. Yousefzadeh P, Shapses SA, Wang X. Vitamin D binding protein impact on 25-hydroxyvitamin D levels under different physiologic and pathologic conditions. Int J Endocrinol. 2014;2014:981581.

    Article  Google Scholar 

  7. Amrein K, Papinutti A, Mathew E, Vila G, Parekh D. Vitamin D and critical illness: what endocrinology can learn from intensive care and vice versa. Endocr Connect. 2018;7:R304–15.

    Article  CAS  Google Scholar 

  8. Lohia P, Kapur S, Benjaram S, Pandey A, Mir T, Seyoum B. Metabolic Syndrome and clinical outcomes in patients infected with COVID-19: does age, sex and race of the patient with Metabolic Syndrome matter? J Diabetes. 2021;13:420–9.

    Article  CAS  Google Scholar 

  9. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5.

    Article  CAS  Google Scholar 

  10. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020;323:2195–8.

    Article  CAS  Google Scholar 

  11. Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, da Silva J, Natarajan P, Morris SB, Fanfair RN, Rogers-Brown J, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19—Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69:545–50.

    Article  CAS  Google Scholar 

  12. Chen LD, Zhang ZY, Wei XJ, Cai YQ, Yao WZ, Wang MH, Huang QF, Zhang XB. Association between cytokine profiles and lung injury in COVID-19 pneumonia. Respir Res. 2020;21:201.

    Article  CAS  Google Scholar 

  13. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–43.

    Article  Google Scholar 

  14. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9:1123–30.

    Article  CAS  Google Scholar 

  15. Radujkovic A, Hippchen T, Tiwari-Heckler S, Dreher S, Boxberger M, Merle U. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients. 2020;12:2757.

    Article  CAS  Google Scholar 

  16. Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, Palumbo A, Di Gioia G, Valerio VN, Resta O. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. J Endocrinol Invest. 2021;44(4):765–71.

    Article  CAS  Google Scholar 

  17. Hernández JL, Nan D, Fernandez-Ayala M, García-Unzueta M, Hernández-Hernández MA, López-Hoyos M, Muñoz-Cacho P, Olmos JM, Gutiérrez-Cuadra M, Ruiz-Cubillán JJ, et al. Vitamin D status in hospitalized patients with SARS-CoV-2 infection. J Clin Endocrinol Metab. 2021;106:e1343–53.

    Article  Google Scholar 

  18. Gaudio A, Murabito AR, Agodi A, Montineri A, Castellino P, Research DOC. Vitamin D levels are reduced at the time of hospital admission in Sicilian SARS-CoV-2-positive patients. Int J Environ Res Public Health. 2021;18(7):3491.

    Article  Google Scholar 

  19. Kerget B, Kerget F, Kızıltunç A, Koçak AO, Araz Ö, Yılmazel Uçar E, Akgün M. Evaluation of the relationship of serum vitamin D levels in COVID-19 patients with clinical course and prognosis. Tuberk Toraks. 2020;68:227–35.

    Article  Google Scholar 

  20. Pizzini A, Aichner M, Sahanic S, Böhm A, Egger A, Hoermann G, Kurz K, Widmann G, Bellmann-Weiler R, Weiss G. Impact of vitamin d deficiency on COVID-19—a prospective analysis from the CovILD registry. Nutrients. 2020;12:2775.

    Article  CAS  Google Scholar 

  21. Abrishami A, Dalili N, Mohammadi Torbati P, Asgari R, Arab-Ahmadi M, Behnam B, Sanei-Taheri M. Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study. Eur J Nutr. 2020.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lohia P, Nguyen P, Patel N, Kapur S. Exploring the link between vitamin D and clinical outcomes in COVID-19. Am J Physiol Endocrinol Metab. 2021;320:E520–6.

    Article  Google Scholar 

  23. IOM (Institute of Medicine). Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2011.

    Google Scholar 

  24. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.

    Article  CAS  Google Scholar 

  25. Brown LL, Cohen B, Tabor D, Zappalà G, Maruvada P, Coates PM. The vitamin D paradox in Black Americans: a systems-based approach to investigating clinical practice, research, and public health—expert panel meeting report. BMC Proc. 2018;12(Suppl 6):6. (eCollection 2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73–8.

    Article  Google Scholar 

  27. Tang X, Du RH, Wang R, Cao TZ, Guan LL, Yang CQ, Zhu Q, Hu M, Li XY, Li Y, et al. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. Chest. 2020;158:195–205.

    Article  CAS  Google Scholar 

  28. Raschke RA, Agarwal S, Rangan P, Heise CW, Curry SC. Discriminant accuracy of the SOFA score for determining the probable mortality of patients with COVID-19 pneumonia requiring mechanical ventilation. JAMA. 2021.

    Article  PubMed  Google Scholar 

Download references





Author information

Authors and Affiliations



PL conceptualized the letter and performed the lead role in literature review, data analysis, data interpretation, drafting the letter, and reviewing it for critical intellectual content. SK contributed equally towards conceptualization, literature review, data analysis, data interpretation, drafting the letter, and reviewing it for critical intellectual content. PP and BS helped in conceptualization of the letter, edited and reviewed the letter for critical intellectual content. All the authors read and approved the final letter; agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Prateek Lohia.

Ethics declarations

Ethics approval and consent to participate

The study was exempt by the Detroit Medical Center (DMC) and Wayne State University Institutional Review Board. (IRB application #20-06-2422).

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lohia, P., Kapur, S., Patel, P. et al. Letter to the editor: Vitamin D levels in acute illness and clinical severity in COVID-19 patients. Respir Res 22, 102 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: